Fuchs D - Search Results

1

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW. Spudich S, et al. Among authors: fuchs d. J Infect Dis. 2011 Sep 1;204(5):753-60. doi: 10.1093/infdis/jir387. J Infect Dis. 2011. PMID: 21844301 Free PMC article.

2

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Abdulle S, et al. Among authors: fuchs d. AIDS. 2002 Nov 8;16(16):2145-9. doi: 10.1097/00002030-200211080-00006. AIDS. 2002. PMID: 12409735

3

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L. Arvidson N, et al. Among authors: fuchs d. AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5. doi: 10.1089/0889222041524625. AIDS Res Hum Retroviruses. 2004. PMID: 15307916

4

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Yilmaz A, et al. Among authors: fuchs d. Scand J Infect Dis. 2004;36(11-12):823-8. doi: 10.1080/00365540410025320. Scand J Infect Dis. 2004. PMID: 15764168 Clinical Trial.

5

Temporarily controlled HIV-1 replication after intravenous immunoglobulin treatment of Guillain-Barré syndrome.

Gisslén M, Fredman P, Fuchs D, Lekman A, Rosengren L. Gisslén M, et al. Among authors: fuchs d. Scand J Infect Dis. 2005;37(11-12):877-81. doi: 10.1080/00365540500277227. Scand J Infect Dis. 2005. PMID: 16308224

6

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

Yilmaz A, Fuchs D, Hagberg L, Nillroth U, Ståhle L, Svensson JO, Gisslén M. Yilmaz A, et al. Among authors: fuchs d. BMC Infect Dis. 2006 Mar 27;6:63. doi: 10.1186/1471-2334-6-63. BMC Infect Dis. 2006. PMID: 16566834 Free PMC article.

7

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.

Andersson LM, Hagberg L, Rosengren L, Fuchs D, Blennow K, Gisslén M. Andersson LM, et al. Among authors: fuchs d. BMC Infect Dis. 2006 Sep 15;6:141. doi: 10.1186/1471-2334-6-141. BMC Infect Dis. 2006. PMID: 16978408 Free PMC article.

8

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Yilmaz A, et al. Among authors: fuchs d. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73. doi: 10.1097/QAI.0b013e31815ace97. J Acquir Immune Defic Syndr. 2008. PMID: 17971711 Free PMC article.

9

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Edén A, et al. Among authors: fuchs d. J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648. J Infect Dis. 2007. PMID: 18190258

10

Cerebrospinal fluid viral load and intrathecal immune activation in individuals infected with different HIV-1 genetic subtypes.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Abdulle S, et al. Among authors: fuchs d. PLoS One. 2008 Apr 16;3(4):e1971. doi: 10.1371/journal.pone.0001971. PLoS One. 2008. PMID: 18414666 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,576 results

Search Page

Filters